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Abstract
Introduction: Autoantibodies and clinical manifestations in polymyositis/dermatomyositis (PM/DM) are affected by
both genetic and environmental factors. The high prevalence of DM and anti-Mi-2 in Central America is thought to
be associated with the high UV index of the area. The prevalences of autoantibodies and the clinical
manifestations of PM/DM were evaluated comparing two cohorts in Mexico.
Methods: Ninety-five Mexican patients with PM/DM (66 DM, 29 PM; 67 Mexico City, 28 Guadalajara) were studied.
Autoantibodies were characterized by immunoprecipitation using 35S-methionine labeled K562 cell extract. Clinical
information was obtained from medical records.
Results: DM represented 69% of PM/DM and anti-Mi-2 was the most common autoantibody (35%), followed by
anti-p155/140 (11%); however, anti-Jo-1 was only 4%. The autoantibody profile in adult-onset DM in Mexico City
versus Guadalajara showed striking differences: anti-Mi-2 was 59% versus 12% (P = 0.0012) whereas anti-p155/140
was 9% versus 35% (P = 0.02), respectively. A strong association of anti-Mi-2 with DM was confirmed and when
clinical features of anti-Mi-2 (+) DM (n = 30) versus anti-Mi-2 (-) DM (n = 36) were compared, the shawl sign (86%
versus 64%, P < 0.05) was more common in the anti-Mi-2 (+) group (P = 0.0001). Levels of creatine phosphokinase
(CPK) were higher in those who were anti-Mi-2 (+) but they responded well to therapy.
Conclusions: Anti-Mi-2 has a high prevalence in Mexican DM and is associated with the shawl sign and high CPK.
The prevalence of anti-Mi-2 and anti-p155/140 was significantly different in Mexico City versus Guadalajara, which
have a similar UV index. This suggests roles of factors other than UV in anti-Mi-2 antibody production.
Introduction
Autoantibodies in polymyositis/dermatomyositis (PM/
DM) are clinically useful biomarkers. Anti-Jo-1 antibodies
that recognize histidyl-tRNA synthetase is a well estab-
lished serological biomarker for PM/DM [1,2] known
for more than 30 years and commercial tests have been
widely available to clinicians [3]. There are many other
autoantibodies specific for a diagnosis of PM/DM (myositis-
specific autoantibodies (MSAs)) and that are also asso-
ciated with unique subsets of the disease and help in
predicting organ involvement, treatment outcome and
prognosis [1,2]; however, their clinical usage is limited
because their standard screening test is radioimmunopreci-
pitation, which has been performed only at a limited num-
ber of institutions in US, UK and a few other European
countries, and Japan. Thus, information on the prevalence
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and clinical association of other MSAs is based on data
from limited sources because data on MSAs in other
countries are scarce. Nevertheless, based on available infor-
mation, the prevalence of MSAs appears to be quite differ-
ent in different countries [4-8] or even within the same
country [9-11], suggesting an interesting interaction of
genetic and environmental factors in the production of
MSAs. In particular, a few previous studies [5,6] reported
an increased percentage of DM and prevalence of anti-
Mi-2 antibodies in PM/DM patients in Central America
and suggested a role of UV radiation in the development
of DM and anti-Mi-2 antibodies. We aimed at determining
the prevalence and clinical association of MSAs in two




Ninety-five consecutive patients with PM/DM (29 PM,
66 DM) who visited adult rheumatology clinics in 2009 to
2012 and were selected based on Bohan’s criteria [12]
were enrolled in the study. Five juvenile-onset DM (JDM)
cases from the same clinics were also enrolled. Twenty-
eight cases (8 PM, 20 DM including 3 JDM) were from
Guadalajara (Hospital Civil Dr. Juan I. Menchaca, Hospital
General Regional 110, IMSS, UMAE, CMNO, IMSS) and
67 cases (21 PM, 46 DM including 2 JDM) were from
Mexico City (Hospital La Raza, IMSS, Hospital 20 de
Noviembre, ISSSTE). Clinical information was obtained
from medical records. The protocol was approved by the
Institutional Review Board (IRB) of the Centro Universi-
tario de Ciencias de la Salud, Universidad de Guadalajara
and by the Hospital Civil de Guadalajara Dr. Juan I.
Menchaca under the register 969/10. This study meets
and is in compliance with all ethical standards in medi-
cine, and informed consent was obtained from all patients
according to the Declaration of Helsinki.
Determination of autoantibodies
Autoantibodies in sera were screened by immunoprecipi-
tation (IP) using 35S-methionine labeled K562 cell
extracts [13]. Specificity of the autoantibodies was deter-
mined using previously described reference sera. Analysis
zof RNA components of the autoantigens was by urea-
PAGE and silver staining (Silver Stain Plus, Bio-Rad,
Hercules, CA, USA) [10]. Recombinant Ro52 protein was
expressed and purified as described [14] and Jo-1 was
purchased from Abazyme (Needham, MA, USA). Anti-
Ro52 and -Jo-1 antibodies were tested by ELISA using
these recombinant proteins at 1:500 serum dilution as
described [8]. Optical density (OD) of the samples was
converted into units using a standard curve created by a
prototype positive serum [15].
Immunofluorescent antinuclear antibodies
Immunofluorescent antinuclear/cytoplasmic antibodies
(HEp-2 ANA slides; INOVA Diagnostics, San Diego,
CA, USA) were tested using a 1:80-diluted human sera
followed by DyLight 488 donkey immunoglobulin G
(IgG) F(ab)’2 anti-human IgG secondary antibodies
(1:200 dilution, g-chain-specific, Jackson Immuno-
Research Laboratories, Inc. West Grove, PA, USA).
Statistical analysis
All parameters were analyzed by the Mann-Whitney
test, Wilcoxon matched-pairs signed ranked test or Fish-
er’s exact test between groups using Prism 6.0b for
Macintosh (GraphPad Software, Inc. La Jolla, CA, USA).
Statistical significance was accepted at P < 0.05. When
statistical significance was observed in comparing the
prevalence of autoantibodies, 95% CI also was
calculated.
Results
DM was dominant in Mexican patients with PM/DM
representing 69% (66/95), consistent with the high per-
centage of DM in Mexico reported in the literature [6].
The percentage of DM in Mexico City and Guadalajara
was similar; 69% (46/67) and 71% (20/28), respectively.
During screening of the serum samples by IP, it was
apparent that anti-Mi-2 [16] and -p155/140 (TIF-1g/a)
[17,18] were the two main autoantibody specificities in
this cohort (Figure 1A). Anti-Jo-1 which is the most
common MSA in the majority of studies from other
countries [4,19], was only 4% while anti-Mi-2 was 35%
and anti-p155/140 was 11% (Table 1). Other MSA speci-
ficities listed were a few percent each and antibodies to
aminoacyl tRNA synthetases (ARS) other than Jo-1,
such as PL-7, PL-12, EJ and OJ, were not found. As in
all previous reports in the literature, anti-Mi-2 (45% in
DM versus 10% in PM, P < 0.0001) and - p155/140
(15% versus 0%, P < 0.05) were mainly found in DM
(Table 1). Anti-MJ and SAE (small ubiquitin-like modifier
activating enzyme) that are also associated with DM [8,20]
were found in 5% and 3%, respectively, of DM patients but
not in PM patients. Patients negative for MSA were 21%
in DM and 69% in PM cohorts (P < 0.0001). Other auto-
antibodies not specific for PM/DM, such as anti-Su/Ago2
[21], Ro60 and Ro52, were found in both PM and DM.
DM patients were classified into adult-onset DM and JDM
(Table 1) and only adult-onset DM patients were further
analyzed comparing patients from Mexico City versus
Guadalajara (Table 2). Adult-onset DM patients from
Guadalajara were slightly younger than those from Mexico
City and striking differences in the prevalence of auto-
antibodies between the two cohorts were noted; the pre-
valence of anti-Mi-2 was 59% (95% CI, 43.3 to 73.7) in
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the Mexico City cohort but only 12% (95% CI, 1.5 to 36.4)
in the Guadalajara cohort (P = 0.0012 by the Fisher exact
test, Table 2). In contrast, the prevalence of anti-p155/140
showed an opposite trend in which the prevalence was 9%
(95% CI, 2.5 to 21.7) in Mexico City DM patients versus
35% (95% CI, 14.2 to 61.7) in Guadalajara DM patients
(P = 0.02). No other significant differences in prevalence
of MSA were noted between the two cohorts. Since the
majority of anti-Mi-2 positive patients had DM (30 DM,
3 PM), the clinical features of the anti-Mi-2 positive
Figure 1 Autoantibodies by immunoprecipitation and CPK levels in Mexican patients with PM/DM. A. Immunoprecipitation using sera
from Mexican patients with PM/DM. 35S-methionine labeled K562 cell extract was immunoprecipitated using sera from PM/DM patients.
Molecular weight markers and positions of Mi-2, TIF-1b, Su and p155/140 (arrowheads) are indicated. B. CPK levels at initial visit are significantly
higher in anti-Mi-2 (+) than anti-Mi-2 (-) DM patients. CPK levels of DM patients at initial visit are plotted. Lines in each group indicate median +
interquartile range. P = 0.0003 by Mann-Whitney. C. CPK levels at initial and last visit in each DM patient compared between anti-Mi-2 (+) and (-)
groups. Top, anti-Mi-2 (+) group, initial versus last visit, P < 0.0001 by Wilcoxon matched pairs test. CPK, creatine phosphokinase; PM/DM,
polymyositis/dermatomyositis.
Table 1 Prevalence of autoantibodies in Mexican patients with PM/DM
PM/DM PM DM Adult-onset DM Juvenile- onset DM
Number 95 29 66 61 5
Age 44.4 48.4 42.8 45.3 18.2
Mean ± SD ± 14.2 ± 10.2 ± 15.3 ± 14.4 ± 9.7
Male 33% 41% 29% 28% 40%
Autoantibodies















MJ/NXP-2 3% 0% 5% 3% 20%
SAE 2% 0% 3% 3% 0%
SRP 3% 7% 2% 2% 0%
PM-Scl 3% 0% 5% 5% 0%
U1RNP 3% 7% 2% 2% 0%
Negative 36% 69%c 21%c 20% 40%
Su/Ago2 8% 7% 9% 10% 0%
Ro60 13% 7% 15% 15% 20%
Ro52d 21% 16% 22% 24% 0%
aP < 0.0001; bP < 0.05; cP < 0.0001 by Fisher exact test; dsome samples were not tested due to availability. All were determined by immunoprecipitation except
anti-Ro52 determined by ELISA. Anti-EJ, PL-7, PL-12, OJ were not found. DM, dermatomyositis; negative, negative for myositis-specifc/related autoantibodies,
anti-Jo-1 to -U1RNP in the table; PM, polymyositis; SAE, small ubiquitin-like modifier activating enzyme; SRP, signal recognition particle.
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patients were compared with those of the anti-Mi-2 nega-
tive patients, only in DM patients (Table 3, left). Since the
number of JDM is small (two from Mexico City and three
from Guadalajara), and most of them were close to age 18
and some were already older than age 18, JDM cases were
included in this analysis. One each from the two cohorts
was positive for anti-Mi-2. In all DM patients (Table 3,
left), men appeared to be more common in anti-Mi-2 (+)
versus (-) (37% versus 22%) but this was not statistically
significant. Among DM features, the shawl sign was more
common in anti-Mi-2 (+) (86% versus 61% in anti-Mi-2
(-), P < 0.05) but the prevalence of heliotrope rash and
the Gottrön sign was similar. However, the prevalence of
the shawl sign was similar when anti-Mi-2 (+) versus (-)
Mexico City DM patients were compared (85% versus
78%); the difference was due to the low prevalence of the
shawl sign in anti-Mi-2 (-) DM patients from Guadalajara
(Mexico City versus Guadalajara, 78% versus 40%, P < 0.05).
Malignancy was found in two cases of PM (a case of cervi-
cal cancer from Guadalajara, no MSA; a case of breast
cancer from Mexico City, anti-Jo-1) and two cases in anti-
Mi-2 (-) DM from Mexico City (a case of breast cancer,
anti-SAE; a case of cervical cancer, anti-p155/140).
Among 10 anti-p155/140 positive DM patients, only one
had a malignancy (cervical cancer), likely related to the
generally young age of the cohort, due to genetic and
environmental factors or other reasons.
The prevalence of interstitial lung disease (ILD) was
low compared with other studies, likely due to the very
low prevalence of anti-ARS antibodies that are fre-
quently associated with ILD (2). CPK at the initial visit
was significantly higher in anti-Mi-2 (+) versus (-) DM
patients (mean 5,369 versus 2,860 IU/L, P < 0.0005)
(Table 3 and Figure 1B) and this trend was the same
when Mexico City DM patients were separately analyzed
(4,800 versus 3,502 IU/L, P < 0.01). Starting lactate dehy-
drogenase (LDH) levels were also higher in the anti-Mi-2
(+) (mean ± SD, 1,517.17 ± 805.02) than in the anti-Mi-2
negative group (841.41 ± 605.86) (P < 0.005 by Mann-
Whitney). None of the patients with anti-Mi-2 (+) had
normal (< 200) CPK at the initial visit whereas 34% of
the anti-Mi-2 (-) patients (P < 0.005) had normal levels,
which was also consistent in Mexico City patients (P <
0.05). All 30 anti-Mi-2 (+) patients had CPK > 1,000 IU/
L at the initial visit compared with only 52% in anti-Mi-2
(-) patients (P < 0.0001). CPK > 5,000 IU/L was more
common in anti-Mi-2 (+) versus anti-Mi-2 (-) patients
(54% versus 14%, P < 0.005). Although CPK levels in
anti-Mi-2 (+) patients were very high, they responded
well to steroid therapy and CPK levels dropped dramati-
cally in most patients (P < 0.0001) (Figure 1C), similar to
the anti-Mi-2 (-) group. At the last visit, the percentage
of patients who had CPK > 500 IU/L was 37% in
the anti-Mi-2 (+) versus 7% in the anti-Mi-2 (-) group
(P = 0.095); however, 45% of the former group had
normal or near normal CPK levels of < 200 IU/L.
Discussion
Autoantibodies to Mi-2 were originally defined by dou-
ble immunodiffusion using calf thymus extract as the
antigen and reported as the first specific serologic mar-
ker of DM [22]. IP was applied and a target antigen
complex was characterized [16], which was later identi-
fied as nucleosome remodeling deacetylase complex
(NuRD) [23]. Clinically, most of the anti-Mi-2 positive
patients are DM [22,24-26]; however, clinical character-
istics associated with anti-Mi-2 have not been studied
extensively due to limited availability of the immunoas-
says and relatively low prevalence in PM/DM. The pre-
sent study, with a total of 33 anti-Mi-2 positive
patients confirmed by IP, is the largest cohort in the
literature with a detailed clinical analysis of anti-Mi-2
positive patients. Clinical features of anti-Mi-2 positive
patients in this study were consistent with previous lit-
erature; they were mostly DM with typical skin mani-
festations, and low prevalence of ILD and malignancy
[24]. Initial CPK levels were higher in the anti-Mi-2
positive DM group compared with the negative group
Table 2 Prevalence of myositis-specific/related































aP = 0.035 by Mann-Whitney; bP = 0.0012; cP = 0.02, by Fisher exact test;
dsome samples were not tested due to availability. All were determined by
immunoprecipitation except anti-Ro52 determined by ELISA. Anti-EJ, PL-7,
PL-12, OJ were not found. DM, dermatomyositis; negative, negative for
myositis-specifc/related autoantibodies, anti-Jo-1 to -U1RNP in the table; PM,
polymyositis; SAE, small ubiquitin-like modifier activating enzyme; SRP, signal
recognition particle.
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(Table 3, Figure 1B). However, they responded well to
steroid treatment in general; CPK levels were reduced
dramatically and normalized in many cases (Table 3,
Figure 1C), consistent with the good prognosis reported
in the literature [24]. The high prevalence of anti-Mi-2
(35%) and the low prevalence of anti-synthetase antibo-
dies (4%) in Mexican PM/DM cases was the most strik-
ing finding in the present study (Table 1) compared
with MSAs in other ethnicities. Anti-Jo-1 which is the
most common MSA in the majority of studies [4,19]
was found only in 4% of the PM/DM patients (7% in
the PM and 3% in the DM). The prevalence of anti-Mi-2
was 35% in PM/DM and was increased to 45% in DM
patients (Table 1). Data on the prevalence of MSAs in
Mexicans are limited to basically one cohort in Mesoa-
merican Mestizo from Mexico City and Guadalajara
[5,6]. Our data are consistent with the study that
reported a high prevalence of anti-Mi-2 and a low preva-
lence of anti-synthetase antibodies, in Mexican PM/DM
[6] (Table 4). A correlation of UV radiation with the
development of DM and production of anti-Mi-2 antibo-
dies has been reported [6,27]. The role of sunlight in
anti-Mi-2 production through alterations in the expres-
sion, subcellular distribution, and/or metabolism of
components of the Mi-2 antigens, has been suggested
[6]. Supporting this hypothesis, regulation of Mi-2
expression by UV through protein translation and stabi-
lity has been shown [28]. Although the high prevalence
of anti-Mi-2 in Mexican PM/DM was interpreted in
association with high UV radiation in the area [6], the
roles of genetic versus environmental factors responsible
for the production of anti-Mi-2 are not fully understood.
Data on MSAs in the Mexican population living in the
US to compare with these data are very limited. One
study reported 8% prevalence of anti-Mi-2 in Mexican
American PM/DM cases in Texas [4], which is not
higher than other ethnicities and is lower than that of
Mestizo living in Mexico [6]. This may seem to be con-
sistent with the role of environmental factors, in parti-
cular UV radiation in anti-Mi-2 antibody production.
However, a significant difference in the prevalence of
anti-Mi-2 in Mexico City versus Guadalajara, which have
comparable UV radiation levels, was observed in two
independent studies by Okada et al. [6] and in the
present study (Table 4). A significant difference in the
prevalence of anti-Mi-2 in PM/DM patients in Mexico
City versus those in Guadalajara (43% versus 14%,
P = 0.0088, Table 4) was found in our study. Interestingly,



















Number 30 36 27 19 3 17
Age 41.3 44.1 42.0 50.3 34.7 37.2
(mean ± SD) ± 14.2 ± 16.3 ± 14.7a ± 15.1a, b ± 4.5 ± 15.3b
% male 37% 22% 33% 26% 67% 18%
Shawl sign 86%c 61%c 85% 78%d 100% 40%d
Heliotrope 74% 79% 71% 89% 100% 69%
Gottrön 78% 74% 79% 78% 67% 69%
Malignancy 0% 6% 0% 11% 0% 0%
Fever 30% 25% 25% 28% 67% 21%
Calcinosis 7% 9% 4% 5% 33% 13%















0%h 34%h 0%i 22%i, j NA 55%j
Initial CPK
> 1,000 IU/L
100%k 52%k 100%l 67%l, m NA 27%m
Initial CPK
> 5,000 IU/L
54%n 14%n 52%o 17%o NA 9%
Last CPK
> 500 IU/L
37%p 7%p 15% 0% NA 18%
Last CPK
< 200 IU/L
45% 69% 45% 67% NA 73%
aP < 0.05; bP < 0.005; cP < 0.05; dP < 0.05; eP < 0.0005; fP < 0.01; gnot significant; hP < 0.005; iP < 0.05; jP = 0.11; kP < 0.0001; lP < 0.005; mP = 0.06; nP < 0.005; 15,
oP < 0.05; pP = 0.095. CPK, creatine phosphokinase; DM, dermatomyositis; ILD, interstitial lung disease; NA, not applicable (due to small numbers).
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a similar pattern of prevalence of anti-Mi-2 in Mexico City
versus Guadalajara PM/DM cases (36% versus 13%, P =
0.03 by Fisher’s exact test based on our calculation, not
shown or discussed in the original study [6]) was also
reported in a previous independent study [6]. When data
from the two studies were combined (see Table 4, row
‘anti-Mi-2 in PM/DM, combined’), the prevalence of anti-
Mi-2 in Mexico City versus Guadalajara patients was 41%
versus 14% (P < 0.0001) with no overlap in 95% CI.
Despite relatively small numbers of DM in the present
study, no overlap in 95% CI was seen in the prevalence of
anti-Mi-2 in Mexico City versus Guadalajara patients (59%
versus 15%, P = 0.001) (Table 4, row anti-Mi-2 in DM).
Very similar data from two independent studies and statis-
tical difference with no overlap of 95% CI support the
interpretation that the difference between the two cities/
cohorts is real. Interestingly, the percentage of DM in PM/
DM in the two locations is similar, approximately 79% in
the previous study [6] and 69% to 71% in the present
study, indicating that the different prevalence of anti-Mi-2
is not a reflection of a difference in PM:DM ratios. These
data suggest that anti-Mi-2 production is affected by
undetermined differences in the two Mexico locations of
genetic and/or environmental factors other than UV radia-
tion alone. While environmental factors are poorly charac-
terized, significant differences in genetic background
of Mexican-Mestizo in the two locations have been
reported [29]. Y-chromosome short-tandem repeats-based
admixture estimates of African: European: Amerindian
in the Mexican-Mestizo population in Mexico City is
4%:46%:50% whereas that in Jalisco County (where Guada-
lajara is located), is 5%:67%:28%, indicating a higher per-
centage of Amerindian derived genes in Mexico City and
European derived gene dominance in Jalisco County [29].
This heterogeneous genetic background among Mexicans
could also be an important issue when interpreting
the reported low prevalence of anti-Mi-2 in Mexican-
Americans >[4] as the admixture of Mexican Americans in
Texas [30] appears to be very similar to that of Jalisco
County (Guadalajara) [29] that also has a low prevalence of
anti-Mi-2 (Table 4). Other environmental factors not char-
acterized in the previous studies may also be important in
an unexplained accumulation of patients with a specific
MSA to a certain year or geographical location, which does
not appear to be due to genetic heterogeneity [10,11].
Conclusions
Both genetic and environmental factors affect the phe-
notypes of autoimmune diseases; however, there are still
unidentified or poorly characterized factors present and
sometimes their contribution may not be apparent. The
present study emphasizes the importance of careful ana-
lysis, considering the heterogeneity of the population
that may also be related to genetic and/or environmen-
tal factors to understand better the mechanisms of MSA
production [31].
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